Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) just unveiled an announcement.
Cosmo Pharmaceuticals announced groundbreaking Phase III results for Clascoterone 5% solution, a potential first major therapeutic breakthrough for male hair loss in over 30 years. The studies showed significant hair count improvements, with one study achieving a 539% increase compared to placebo. The solution, which blocks DHT at the hair follicle receptor, demonstrated a favorable safety profile and could redefine androgenetic alopecia treatment. Cosmo is preparing for regulatory submissions in the USA and Europe, aiming to address a market with significant unmet demand.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF130.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life science company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures advanced solutions to meet critical medical needs and improve the standard of care. Founded in 1997 and headquartered in Dublin, Ireland, Cosmo operates globally with offices in the USA and Italy.
Average Trading Volume: 21,697
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.1B
For a thorough assessment of COPN stock, go to TipRanks’ Stock Analysis page.